Fly Intel: Top five analyst initiations » 10:0907/0207/02/20
FLIR, PEAK, TRHC, APDN, ES
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Flir Systems (FLIR) initiated with a Buy at Canaccord. 2. Healthpeak (PEAK) initiated with a Hold at Berenberg. 3. Tabula Rasa HealthCare (TRHC) initiated with a Buy at SunTrust. 4. Applied DNA Sciences (APDN) initiated with a Buy at H.C. Wainwright. 5. Eversource (ES) assumed with an Underweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
Applied DNA Sciences initiated with a Buy at H.C. Wainwright » 06:0507/0207/02/20
H.C. Wainwright analyst…
H.C. Wainwright analyst Yi Chen initiated coverage of Applied DNA Sciences with a Buy rating and $18 price target. The company's COVID-19 vaccine candidates have produced neutralizing antibodies in mice and results from the linear DNA version in animal studies are slated to be reported in the coming days, Chen tells investors in a research note. The analyst cites Applied's "rapid responses and the substantial markets of COVID-19 testing" for the Buy rating.
|Over a week ago|
Two new option listings and ten option delistings on June 22nd » 08:3006/2206/22/20
APDN, CGIX, FDEF, NIHD, SDRL
New option listings for…
New option listings for June 22nd include Premier Financial Corporation (PFC) and Seadrill Ltd (SDRLF). Option delistings effective June 22nd include Applied DNA Sciences (APDN), Cancer Genetics (CGIX), CARBO Ceramics Inc (CRRTQ), First Defiance Financial Corporation (FDEF), Morningstar Dividend (FDL), Foresight Energy Partners LP (Units) (FELPQ), Hornbeck Offshore Services Inc (HOSSQ), NII Holdings (NIHD), Seadrill Ltd (SDRL), and Sandridge Mississippian Trust II (Units) (SDRMU).
Applied DNA announces $40,000 economic development grant for COVID-19 programs » 11:3706/0906/09/20
Applied DNA Sciences…
Applied DNA Sciences announced it secured a $40,000 economic development grant from National Grid to support the company's efforts associated with the manufacture of COVID-19-related therapeutics and diagnostics programs. "We are grateful for National Grid and New York State's focus on the Long Island community in this time of crisis. This funding will be used to increase our capacity to deliver quantities of our RT-PCR test for COVID-19 that was recently approved under Emergency Use Authorization by the FDA for clinical use, and to support the pathway toward human trials of selected vaccine candidates we have jointly developed with Takis Biotech. Our orchestrated approach to our development programs aimed at vanquishing COVID-19 we believe is unique, and we share a deep motivation as fellow Long Islanders to support local communities and governments, that are working tirelessly to manage within the pandemic," said Dr. James Hayward, president and CEO at Applied DNA.
Applied DNA Sciences provides update on linear-DNA COVID-19 vaccine candidates » 08:3006/0806/08/20
Applied DNA Sciences…
Applied DNA Sciences provided an update related to the development of linear-DNA form of COVID-19 vaccine candidates with development partner Takis Biotech. Subsequent to the company's announcement that first injections of plasmid-based DNA vaccine candidates developed by Takis produced neutralizing antibodies in test animals, linear DNA versions of the vaccine candidates manufactured by Applied DNA began dose-response trials the results of which the company expects to publish in June. The companies' development program utilizes the plasmid-based DNA templates to determine baseline results for the efficacy of the vaccine candidates in preclinical animal models. Based on previous studies with its linear-DNA, Applied DNA anticipates similar results from its linear DNA versions of the vaccine candidates in preclinical animal models with the potential added advantage of reduced risk of antibiotic resistance and genomic integration and speed of production.
|Over a month ago|
Maxim Group to hold a virtual conference » 09:2505/2705/27/20
APDN, BIOC, BNGO, CAPR, CODX, DXR, LCTX, MESO, PSTI, VNRX
Maxim Group Virtual…
Maxim Group Virtual COVID-19 Conference will be held on May 27.
Applied DNA Sciences files $50M mixed securities shelf 16:1005/2105/21/20
Applied DNA Sciences receives FDA EUA for COVID-19 assay kit » 05:3505/1405/14/20
Applied DNA Sciences…
Applied DNA Sciences announced that the FDA has provided Emergency Use Authorization, or EUA, for the clinical use of the company's patent-pending Linea COVID-19 RT-PCR test for COVID-19. Clinical laboratories in the United States certified under Clinical Laboratory Improvement Amendments, or CLIA, to perform hi complexity tests. CLIA labs can immediately begin ordering and using the Linea COVID-19 assay kit to detect SARS-CoV-2, the virus that causes COVID-19. The Linea COVID-19 assay kit is an rRT-PCR-based assay designed to detect specific highly conserved target sequences of the SARS-CoV-2 Spike gene. The Linea COVID-19 assay is an advanced single-well multiplex test that allows for simple set up and higher-throughput as compared to tests that require multiple wells per test. The Linea COVID-19 assay is approved to run on the FDA-approved Applied Biosystems QuantStudio Dx real-time PCR instrument, which allows for testing results for up to 94 samples within one hour, or more than 2,000 tests in 24 hours per device.
Applied DNA Sciences applies to FDA for EUA for COVID-19 diagnostic kit » 09:3305/0505/05/20
Applied DNA Sciences…
Applied DNA Sciences announced that it applied prior to the end of April for U.S. Food and Drug Administration Emergency Use Authorization for its Linea COVID-19 diagnostic candidate to detect SARS-CoV-2, the novel coronavirus that causes the disease COVID-19. Validation for the EUA was completed in collaboration with Stony Brook University Hospital; the company's neighbor and collaborator on campus. The assay is designed to be run in high-throughput workflows that enable same-day results to be transmitted to the ordering physician. In a spirit of continuous innovation and improvement of the end-to-end process of patient diagnosis, the company is investigating methods to enhance the assay to increase the ease of patient sampling by using saliva instead of invasive nasopharyngeal swabbing methods. Applied DNA makes clear that while the company has filed an EUA with the U.S. FDA, the U.S. FDA has not yet approved the company's diagnostic and there is no guarantee that any EUA will be approved. In addition, numerous other SARS-CoV-2 diagnostic assays are under development by other third parties or have been granted EUA approval by U.S. FDA, any of which may be more successful than the company's assay, and even if the company's assay gains EUA approval, the assay may generate only limited revenue and profits for the company.
Applied DNA Sciences price target raised to $18 from $8 at Maxim » 09:0305/0505/05/20
Maxim analyst Anthony…
Maxim analyst Anthony Vendetti raised the firm's price target on Applied DNA Sciences to $18 from $8 and keeps a Buy rating on the shares. The analyst cites the company's announcement yesterday regarding the production of neutralizing antibodies against the COVID-19 virus following the vaccination of DNA in mice. While still pre-clinical, Vendetti contends that the findings mark a "key piece of compelling data" toward a possibility of a viable vaccine candidate.